P0216CHECK POINT INHIBITORS AND CANCER. RENAL ADVERSE EVENTS: CASE SERIES
Abstract Background and Aims The treatment of cancer with check point inhibitors (CPI) has demonstrated significant benefits. CPI initiate antitumor immunity through negative regulatory components in T cells. However, these agents are associated with adverse events related to the immune system that...
Saved in:
Published in | Nephrology, dialysis, transplantation Vol. 35; no. Supplement_3 |
---|---|
Main Authors | , , , , , , |
Format | Journal Article |
Language | English |
Published |
Oxford University Press
01.06.2020
|
Online Access | Get full text |
Cover
Loading…
Abstract | Abstract
Background and Aims
The treatment of cancer with check point inhibitors (CPI) has demonstrated significant benefits. CPI initiate antitumor immunity through negative regulatory components in T cells. However, these agents are associated with adverse events related to the immune system that can affect several organs. Initially, a low incidence of renal adverse events was reported, although recent data suggest an incidence between 9.9% and 29%. The objective of the study was to describe a case series that presented renal dysfunction related to CPI treatment.
Method
11 patients were studied retrospectively (67% males, mean age 69 ± 13 years), diagnosed with Neoplasms (9 advanced lung cancer, 7 of them metastatic and 2 metastatic melanomas) treated with CPI, who developed renal dysfunction. 5 patients with lung cancer were treated with Pembrolizumab, 3 with Nivolumab and 1 with Pembrolizumab + Ipilimumab combination. Patients with melanoma received Pembrolizumab. In 55% of the cases, immunotherapy was used as first line of antitumor treatment. Demographic and clinical-analytical data were collected, as well as the evolution of renal function.
Results
The median plasma creatinine prior to receiving treatment with CPI was 0.9 mg/dl [0.67-1.5]. The maximum creatinine reached after treatment with CPI was 2.5 mg/dl [1.8-7.5] with Pembrolizumab, 5.4 mg/dl [3-6.7] with Nivolumab and 4.3 mg/dl with the combination Pembrolizumab + Ipilimumab. Renal dysfunction occurred in the fifth cycle of treatment with Pembrolizumab and in the third cycle with Nivolumab and Pembrolizumab + Ipilimumab.
All patients received steroids (1mg/kg) and CPI were permanently discontinued in 3 patients with Pembrolizumab (43%), 1 with Nivolumab (33.3%) and 1 with Pembrolizumab + Ipilimumab (100%). Renal biopsy was performed in 4 patients who initially did not respond to steroids, resulting in acute tubulo-interstitial nephritis (ATIN), 1 of them with granuloma formation and worse renal evolution.
All patients recovered renal function partially or totally, except 1 treated with Pembrolizumab who remained with advanced kidney disease. Tumor progression was observed in 3 patients and 2 died.
Conclusion
CPI have demonstrated significant clinical benefits in the regression and prolonged stabilization of many tumors. The main cause of renal dysfunction after the use of CPI in our patients was the ATIN, with a good initial response to steroids and drug suspension. The presence of granulomas in renal biopsy confers a poor prognosis. It is an increasingly frequent entity in clinical practice, and because of its complicated management, it requires a multidisciplinary approach. |
---|---|
AbstractList | Abstract
Background and Aims
The treatment of cancer with check point inhibitors (CPI) has demonstrated significant benefits. CPI initiate antitumor immunity through negative regulatory components in T cells. However, these agents are associated with adverse events related to the immune system that can affect several organs. Initially, a low incidence of renal adverse events was reported, although recent data suggest an incidence between 9.9% and 29%. The objective of the study was to describe a case series that presented renal dysfunction related to CPI treatment.
Method
11 patients were studied retrospectively (67% males, mean age 69 ± 13 years), diagnosed with Neoplasms (9 advanced lung cancer, 7 of them metastatic and 2 metastatic melanomas) treated with CPI, who developed renal dysfunction. 5 patients with lung cancer were treated with Pembrolizumab, 3 with Nivolumab and 1 with Pembrolizumab + Ipilimumab combination. Patients with melanoma received Pembrolizumab. In 55% of the cases, immunotherapy was used as first line of antitumor treatment. Demographic and clinical-analytical data were collected, as well as the evolution of renal function.
Results
The median plasma creatinine prior to receiving treatment with CPI was 0.9 mg/dl [0.67-1.5]. The maximum creatinine reached after treatment with CPI was 2.5 mg/dl [1.8-7.5] with Pembrolizumab, 5.4 mg/dl [3-6.7] with Nivolumab and 4.3 mg/dl with the combination Pembrolizumab + Ipilimumab. Renal dysfunction occurred in the fifth cycle of treatment with Pembrolizumab and in the third cycle with Nivolumab and Pembrolizumab + Ipilimumab.
All patients received steroids (1mg/kg) and CPI were permanently discontinued in 3 patients with Pembrolizumab (43%), 1 with Nivolumab (33.3%) and 1 with Pembrolizumab + Ipilimumab (100%). Renal biopsy was performed in 4 patients who initially did not respond to steroids, resulting in acute tubulo-interstitial nephritis (ATIN), 1 of them with granuloma formation and worse renal evolution.
All patients recovered renal function partially or totally, except 1 treated with Pembrolizumab who remained with advanced kidney disease. Tumor progression was observed in 3 patients and 2 died.
Conclusion
CPI have demonstrated significant clinical benefits in the regression and prolonged stabilization of many tumors. The main cause of renal dysfunction after the use of CPI in our patients was the ATIN, with a good initial response to steroids and drug suspension. The presence of granulomas in renal biopsy confers a poor prognosis. It is an increasingly frequent entity in clinical practice, and because of its complicated management, it requires a multidisciplinary approach. |
Author | Esparza Martín, Noemí Pérez Suárez, Germán Ramírez Puga, Ana Rodríguez Abreu, Delvys González Nuez, Selene Fernández Granados, Saulo Jesús García Cantón, César |
Author_xml | – sequence: 1 givenname: Selene surname: González Nuez fullname: González Nuez, Selene organization: Hospital Insular, Nephrology, Las Palmas de Gran Canaria, Spain – sequence: 2 givenname: Germán surname: Pérez Suárez fullname: Pérez Suárez, Germán organization: Hospital Insular, Nephrology, Las Palmas de Gran Canaria, Spain – sequence: 3 givenname: Ana surname: Ramírez Puga fullname: Ramírez Puga, Ana organization: Hospital Insular, Oncology, Las Palmas de Gran Canaria, Spain – sequence: 4 givenname: Delvys surname: Rodríguez Abreu fullname: Rodríguez Abreu, Delvys organization: Hospital Insular, Oncology, Las Palmas de Gran Canaria, Spain – sequence: 5 givenname: Saulo Jesús surname: Fernández Granados fullname: Fernández Granados, Saulo Jesús organization: Hospital Insular, Nephrology, Las Palmas de Gran Canaria, Spain – sequence: 6 givenname: Noemí surname: Esparza Martín fullname: Esparza Martín, Noemí organization: Hospital Insular, Nephrology, Las Palmas de Gran Canaria, Spain – sequence: 7 givenname: César surname: García Cantón fullname: García Cantón, César organization: Hospital Insular, Nephrology, Las Palmas de Gran Canaria, Spain |
BookMark | eNqNkNtOg0AQhjemJtLqA3i3DyDtzC6n9Q7pKhsJNIC9JcthjUahAb3w7cW2D-DV5M98_yTzLcmiH_qOkFuENYLgm7792rwardFh6x0w9C6IhY4HNuOBuyDWzKANLogrspymdwAQzPctoo5wFMvome4ylZZUpbF6UGWWFzRMtzQK00jma5rLNExouN3LvJBU7mVaFvfzdg6FzJUsrsml0R9Td3OeK_LyKMsotpPsSUVhYjfog2e3rdCIteF1IDw3aHwTmIYJx_G4dljrG2Y64zEUDBivTWNcaIIWsK19cALN-Yrg6W4zDtM0dqY6jG-fevypEKo_F9Xsojq7qI7vzZ27U2f4PvwD_wXfy1yN |
CitedBy_id | crossref_primary_10_1007_s40278_020_87334_4 |
ContentType | Journal Article |
Copyright | The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved 2020 |
Copyright_xml | – notice: The Author(s) 2020. Published by Oxford University Press on behalf of ERA-EDTA. All rights reserved 2020 |
DBID | AAYXX CITATION |
DOI | 10.1093/ndt/gfaa142.P0216 |
DatabaseName | CrossRef |
DatabaseTitle | CrossRef |
DatabaseTitleList | CrossRef |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
DocumentTitleAlternate | 57th ERA-EDTA Congress Abstracts |
EISSN | 1460-2385 |
ExternalDocumentID | 10_1093_ndt_gfaa142_P0216 10.1093/ndt/gfaa142.P0216 |
GroupedDBID | --- -E4 .2P .I3 .XZ .ZR 0R~ 123 18M 1TH 29M 2WC 4.4 482 48X 53G 5RE 5VS 5WA 5WD 70D AABZA AACZT AAHTB AAJKP AAMDB AAMVS AAOGV AAPNW AAPQZ AAPXW AARHZ AASNB AAUAY AAUQX AAVAP ABEUO ABIXL ABJNI ABKDP ABNHQ ABNKS ABOCM ABPEJ ABPTD ABQLI ABQNK ABWST ABXVV ABZBJ ACGFO ACGFS ACPRK ACUFI ACUTJ ACUTO ACYHN ADBBV ADEYI ADEZT ADGZP ADHKW ADHZD ADIPN ADJQC ADOCK ADQBN ADRIX ADRTK ADVEK ADYVW ADZXQ AEGPL AEGXH AEJOX AEKSI AEMDU AENEX AENZO AEPUE AETBJ AEWNT AFFZL AFIYH AFOFC AFXAL AFXEN AGINJ AGKEF AGQXC AGSYK AGUTN AHMBA AHXPO AIAGR AIJHB AJEEA AKWXX ALMA_UNASSIGNED_HOLDINGS ALUQC APIBT APWMN ATGXG AXUDD BAWUL BAYMD BCRHZ BEYMZ BHONS BTRTY BVRKM C45 CDBKE CS3 CZ4 DAKXR DIK DILTD DU5 D~K E3Z EBS EE~ ENERS F5P F9B FECEO FLUFQ FOEOM FOTVD FQBLK GAUVT GJXCC GX1 H13 H5~ HAR HW0 HZ~ IOX J21 JXSIZ KAQDR KBUDW KOP KQ8 KSI KSN M-Z M49 MHKGH ML0 N9A NGC NOMLY NOYVH NU- O9- OAUYM OAWHX OCZFY ODMLO OHH OJQWA OJZSN OK1 OPAEJ OVD OWPYF P2P P6G PAFKI PEELM PQQKQ Q1. Q5Y R44 RD5 ROL ROX ROZ RUSNO RW1 RXO SDH TCURE TEORI TJX TR2 W8F WH7 WOQ X7H YAYTL YKOAZ YXANX ZKX ~91 AAYXX CITATION |
ID | FETCH-LOGICAL-c1706-dd9a11bf3b89658c7f8fc294463a42d7f2fef62192023bfcf50c8d01db7048a33 |
ISSN | 0931-0509 |
IngestDate | Thu Sep 12 19:27:24 EDT 2024 Wed Sep 11 04:47:15 EDT 2024 |
IsDoiOpenAccess | false |
IsOpenAccess | true |
IsPeerReviewed | true |
IsScholarly | true |
Issue | Supplement_3 |
Language | English |
License | This article is published and distributed under the terms of the Oxford University Press, Standard Journals Publication Model (https://academic.oup.com/journals/pages/open_access/funder_policies/chorus/standard_publication_model) |
LinkModel | OpenURL |
MergedId | FETCHMERGED-LOGICAL-c1706-dd9a11bf3b89658c7f8fc294463a42d7f2fef62192023bfcf50c8d01db7048a33 |
OpenAccessLink | https://academic.oup.com/ndt/article-pdf/35/Supplement_3/gfaa142.P0216/33361339/gfaa142.p0216.pdf |
ParticipantIDs | crossref_primary_10_1093_ndt_gfaa142_P0216 oup_primary_10_1093_ndt_gfaa142_P0216 |
PublicationCentury | 2000 |
PublicationDate | 20200601 2020-06-01 |
PublicationDateYYYYMMDD | 2020-06-01 |
PublicationDate_xml | – month: 06 year: 2020 text: 20200601 day: 01 |
PublicationDecade | 2020 |
PublicationTitle | Nephrology, dialysis, transplantation |
PublicationYear | 2020 |
Publisher | Oxford University Press |
Publisher_xml | – name: Oxford University Press |
SSID | ssj0009277 |
Score | 2.3645089 |
Snippet | Abstract
Background and Aims
The treatment of cancer with check point inhibitors (CPI) has demonstrated significant benefits. CPI initiate antitumor immunity... |
SourceID | crossref oup |
SourceType | Aggregation Database Publisher |
Title | P0216CHECK POINT INHIBITORS AND CANCER. RENAL ADVERSE EVENTS: CASE SERIES |
Volume | 35 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwGLXKkBAviKsYN_kBXojSJXEuLW8lzdYwkVVJhvYW2Yk9CVUpqhok-sf4e3y2c2nREIyXKLUst_V35GN_l2OE3np2QCtWCdMPODVdIohJCSdmUDpcTLhjE6oSZBN_cel-uvKuRqOfe1lLzZaNy92NdSX_Y1VoA7vKKtlbWLYfFBrgHewLT7AwPP_JxkugTj9cROG5sbyIk9yIk0X8Mc4v0kzJRoXy5pl0bKSRzO8BBorSLDKiL1GSZ9IVEM7gYwZHuXZL-LWTcgIL91UssrJEypbI962SQl_R-jCAf7audyribq_4zkga7ZXOJKP1uFnqkPwGOmSN7rzR_c6AHHTDUJVGdctcdl82rfO37ikkXVc6xD-_hi8zZnCub_Tqufr-48CT4VhDxlXnkiS2KfVoNDfpBdn1LRO2Fd7-iq0FTlpkqttPlSu1IDdygtbLqisgtdNrQantOmNln4ECu7D_b8zY5yvqSD0pYJCiHaJQQ9xBd51g6slc0nl8Pqg9O-rKz_4PdeH0KTmBIU4OfsXBhkgWWe7tb_KH6EF7MMEzjbJHaMTrx-je5zb14gmKB7BhBTY8gA0D2HALNqzAhluwYQ22D1hCDWuoPUWXp1EeLsz2Hg6zlOJKZlVNqW0zQdhESgWVgZiI0pm6rk-o61SBcAQXPlAfGJUwUQrPKieVZVcsAH6ghDxDR_W65s8R5hahjAJxlLblCioLvQmTIpAVo8zz_GP0vpuM4puWWyn-OPnH6B1M19_7vbjNoC_R_QGbr9DRdtPw17Dv3LI3ysa_APCPcWk |
link.rule.ids | 315,786,790,27955,27956 |
linkProvider | Flying Publisher |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=P0216CHECK+POINT+INHIBITORS+AND+CANCER.+RENAL+ADVERSE+EVENTS%3A+CASE+SERIES&rft.jtitle=Nephrology%2C+dialysis%2C+transplantation&rft.au=Gonz%C3%A1lez+Nuez%2C+Selene&rft.au=P%C3%A9rez+Su%C3%A1rez%2C+Germ%C3%A1n&rft.au=Ram%C3%ADrez+Puga%2C+Ana&rft.au=Rodr%C3%ADguez+Abreu%2C+Delvys&rft.date=2020-06-01&rft.issn=0931-0509&rft.eissn=1460-2385&rft.volume=35&rft.issue=Supplement_3&rft_id=info:doi/10.1093%2Fndt%2Fgfaa142.P0216&rft.externalDBID=n%2Fa&rft.externalDocID=10_1093_ndt_gfaa142_P0216 |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0931-0509&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0931-0509&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0931-0509&client=summon |